Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07154706 |
| Title | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) |
| Acronym | TRUST-IV |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Nuvation Bio Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South | RECRUITING | Austin | Texas | 78731 | United States | Details |
| Virginia Cancer Specialists | RECRUITING | Fairfax | Virginia | 22031 | United States | Details |